Shares of Advaxis, Inc. (NASDAQ:ADXS) were down 0% during mid-day trading on Monday . The stock traded as low as $2.92 and last traded at $2.98. Approximately 1,187,409 shares traded hands during mid-day trading, an increase of 26% from the average daily volume of 942,074 shares. The stock had previously closed at $2.98.

Several analysts have issued reports on ADXS shares. HC Wainwright reaffirmed a “buy” rating and issued a $23.00 target price on shares of Advaxis in a research note on Friday, September 15th. ValuEngine lowered Advaxis from a “sell” rating to a “strong sell” rating in a research note on Tuesday, October 3rd. Finally, Cantor Fitzgerald set a $19.00 target price on Advaxis and gave the stock a “buy” rating in a research note on Friday, December 22nd.

The firm has a market cap of $122.38, a PE ratio of -1.30 and a beta of 1.91.

Advaxis (NASDAQ:ADXS) last announced its quarterly earnings data on Wednesday, December 20th. The biotechnology company reported ($0.57) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($0.02). Advaxis had a negative net margin of 776.63% and a negative return on equity of 114.00%. The company had revenue of $1.76 million during the quarter, compared to the consensus estimate of $3.05 million. equities research analysts anticipate that Advaxis, Inc. will post -2.36 EPS for the current year.

In other Advaxis news, insider Robert Petit sold 12,625 shares of the business’s stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $3.19, for a total value of $40,273.75. Following the completion of the sale, the insider now owns 237,265 shares in the company, valued at $756,875.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Sara Bonstein sold 12,734 shares of the business’s stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $3.19, for a total value of $40,621.46. Following the completion of the sale, the chief financial officer now owns 244,504 shares of the company’s stock, valued at approximately $779,967.76. The disclosure for this sale can be found here. Insiders sold 638,192 shares of company stock valued at $2,702,615 in the last quarter. Corporate insiders own 7.21% of the company’s stock.

Several institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in shares of Advaxis by 7.2% during the second quarter. Vanguard Group Inc. now owns 1,782,990 shares of the biotechnology company’s stock valued at $11,572,000 after acquiring an additional 119,980 shares in the last quarter. State Street Corp raised its holdings in shares of Advaxis by 7.8% during the second quarter. State Street Corp now owns 670,134 shares of the biotechnology company’s stock valued at $4,352,000 after acquiring an additional 48,485 shares in the last quarter. Northern Trust Corp raised its holdings in shares of Advaxis by 4.4% during the second quarter. Northern Trust Corp now owns 456,817 shares of the biotechnology company’s stock valued at $2,965,000 after acquiring an additional 19,434 shares in the last quarter. Nexthera Capital LP raised its holdings in shares of Advaxis by 160.3% during the second quarter. Nexthera Capital LP now owns 252,000 shares of the biotechnology company’s stock valued at $1,635,000 after acquiring an additional 155,200 shares in the last quarter. Finally, DAFNA Capital Management LLC raised its holdings in shares of Advaxis by 43.6% during the second quarter. DAFNA Capital Management LLC now owns 247,000 shares of the biotechnology company’s stock valued at $1,603,000 after acquiring an additional 75,000 shares in the last quarter. Institutional investors own 41.65% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.watchlistnews.com/advaxis-adxs-shares-down-0/1798950.html.

About Advaxis

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with Analyst Ratings Network's FREE daily email newsletter.